Monday, 04 March 2024

Monoclonal antibody drug by GSK Singapore approved to treat chronic rhinosinusitis

07 February 2023 | News

Nucala (mepolizumab) is developed to treat Chronic Rhinosinusitis with Nasal Polyps and Hyper Eosinophilic Syndrome

Photo Credit: Freepik

Photo Credit: Freepik

GSK Singapore announced that Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), has been approved for treatment in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and hypereosinophilic syndrome (HES).

Eosinophil-driven diseases are inflammatory conditions associated with elevated levels of eosinophils, a type of white blood cell. CRSwNP is a condition in which patients develop soft tissue growths called nasal polyps which can cause chronic symptoms such as nasal obstruction, loss of smell and discharge.

Raakhi Sippy, Vice President and General Manager – GSK Singapore, said: "These approvals mark a significant chapter for patients in Singapore who are burdened by eosinophilic-driven diseases. To further the impact and help more patients, we are committed to exploring the role of IL-5 inhibition in eosinophil-driven diseases."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account